Temelimab is an IgG4 monoclonal antibody that targets the human endogenous retroviral envelope protein HERV-W-Env. Temelimab has been investigated for the treatment of multiple sclerosis.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.